ArticleBMC neurology2024

A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy.

Sharon Wolters et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.